332 related articles for article (PubMed ID: 29899215)
1. Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance.
Nguyen HS; Shabani S; Awad AJ; Kaushal M; Doan N
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899215
[TBL] [Abstract][Full Text] [Related]
2. Identification of radiation responsive genes and transcriptome profiling via complete RNA sequencing in a stable radioresistant U87 glioblastoma model.
Doan NB; Nguyen HS; Alhajala HS; Jaber B; Al-Gizawiy MM; Ahn EE; Mueller WM; Chitambar CR; Mirza SP; Schmainda KM
Oncotarget; 2018 May; 9(34):23532-23542. PubMed ID: 29805753
[TBL] [Abstract][Full Text] [Related]
3. Acid ceramidase confers radioresistance to glioblastoma cells.
Doan NB; Nguyen HS; Al-Gizawiy MM; Mueller WM; Sabbadini RA; Rand SD; Connelly JM; Chitambar CR; Schmainda KM; Mirza SP
Oncol Rep; 2017 Oct; 38(4):1932-1940. PubMed ID: 28765947
[TBL] [Abstract][Full Text] [Related]
4. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
5. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
6. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
7. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
9. Applications of emerging molecular technologies in glioblastoma multiforme.
Kumar HR; Zhong X; Sandoval JA; Hickey RJ; Malkas LH
Expert Rev Neurother; 2008 Oct; 8(10):1497-506. PubMed ID: 18928343
[TBL] [Abstract][Full Text] [Related]
10. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Messaoudi K; Clavreul A; Lagarce F
Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
[TBL] [Abstract][Full Text] [Related]
11. Global MicroRNA Expression Profiling Identifies Unique MicroRNA Pattern of Radioresistant Glioblastoma Cells.
Ondracek J; Fadrus P; Sana J; Besse A; Loja T; Vecera M; Radova L; Smrcka M; Slampa P; Slaby O
Anticancer Res; 2017 Mar; 37(3):1099-1104. PubMed ID: 28314270
[TBL] [Abstract][Full Text] [Related]
12. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma.
Wu H; Guo C; Wang C; Xu J; Zheng S; Duan J; Li Y; Bai H; Xu Q; Ning F; Wang F; Yang Q
Cancer Sci; 2023 Jun; 114(6):2609-2621. PubMed ID: 36853018
[TBL] [Abstract][Full Text] [Related]
13. SDC1-TGM2-FLOT1-BHMT complex determines radiosensitivity of glioblastoma by influencing the fusion of autophagosomes with lysosomes.
Zeng L; Zheng W; Liu X; Zhou Y; Jin X; Xiao Y; Bai Y; Pan Y; Zhang J; Shao C
Theranostics; 2023; 13(11):3725-3743. PubMed ID: 37441590
[No Abstract] [Full Text] [Related]
14. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma.
Qazi MA; Vora P; Venugopal C; Sidhu SS; Moffat J; Swanton C; Singh SK
Ann Oncol; 2017 Jul; 28(7):1448-1456. PubMed ID: 28407030
[TBL] [Abstract][Full Text] [Related]
15. ID1 affects the efficacy of radiotherapy in glioblastoma through inhibition of DNA repair pathways.
Guo Q; Guo P; Mao Q; Lan J; Lin Y; Jiang J; Qiu Y
Med Oncol; 2013 Mar; 30(1):325. PubMed ID: 23377983
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma precision therapy: From the bench to the clinic.
Zhou Y; Wu W; Bi H; Yang D; Zhang C
Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells.
Maachani UB; Shankavaram U; Kramp T; Tofilon PJ; Camphausen K; Tandle AT
Oncotarget; 2016 Nov; 7(47):77365-77377. PubMed ID: 27764801
[TBL] [Abstract][Full Text] [Related]
18. Recognizing and correcting failures in glioblastoma treatment.
Shah AH; Graham R; Bregy A; Thambuswamy M; Komotar RJ
Cancer Invest; 2014 Jul; 32(6):299-302. PubMed ID: 24766304
[TBL] [Abstract][Full Text] [Related]
19. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs as Multifaceted Players in Glioblastoma Multiforme.
Mercatelli N; Galardi S; Ciafrè SA
Int Rev Cell Mol Biol; 2017; 333():269-323. PubMed ID: 28729027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
